openPR Logo
Press release

Pneumonia Drug Development Pipeline Review, 2017

10-24-2017 09:31 AM CET | Health & Medicine

Press release from: ReportsWorldwide

This report provides an overview of the pipeline landscape for pneumonia disorders. The report provides comprehensive information on the therapeutics under development and key players involved in therapeutic development for Community Acquired Pneumonia, Hospital Acquired Pneumonia and Ventilator Associated Pneumonia and features dormant and discontinued projects.

Summary

Community acquired pneumonia is pneumonia contracted by a person who has had little contact with the healthcare system, with common symptoms including cough, fever and shortness of breath. Risk factors include chronic lung disease, cigarette smoking, immune system problems and surgery.
Hospital acquired pneumonia refers to any pneumonia contracted by a patient in a hospital at least 48-72 hours after being admitted. Signs and symptoms include malaise, fever, chills, rigor, cough, dyspnea, and chest pain, but in ventilated patients, pneumonia usually manifests as worsening oxygenation and increased tracheal secretions.

Finally, ventilator associated pneumonia is pneumonia that occurs in people who are on mechanical ventilation breathing machines in hospitals. As such the disease typically affects critically ill patients and increases the risk of mortality. Signs and symptoms include fever or low body temperature, new purulent sputum and hypoxemia.

The size of these pipelines ranges from 20 products in community acquired pneumonia to 39 in hospital acquired pneumonia. Across all three of these indications bacterial targets such as DNA gyrase and ribosomal DNA are the most common targets, closely reflecting the current treatment landscape of these diseases.

Scope

- Which companies are the most active within the pipeline for pneumonia therapeutics?
- Which pharmaceutical approaches are the most prominent at each stage of the pipeline and within each indication?
- To what extent do universities and institutions play a role within this pipeline, compared to pharmaceutical companies?
- What are the most important R&D milestones and data publications to have happened in the field of pneumonia?

To Get Sample Copy of Report please visit @ https://www.reportsworldwide.com/enquiry?report_id=41646

Reasons to buy

- Understand the overall pipeline, with an at-a-glance overview of all products in therapeutic development for each indication
- Assess the products in development in granular detail, with an up-to-date overview of each individual pipeline program in each indication, and a comprehensive picture of recent updates and milestones for each
- Analyze the companies, institutions and universities currently operating in the pipeline, and the products being fielded by each of these
- Understand the composition of the pipeline in terms of molecule type, molecular target, mechanism of action and route of administration

To view a detailed description and Table of Contents please visit: https://www.reportsworldwide.com/report/pneumonia-drug-development-pipeline-review-2017

About ReportsWorldwide.com

ReportsWorldwide.com is a leading provider of global market intelligence reports and services. With research reports from top publishers, consulting and advisory firms, ReportsWorldwide.com offers instant online access to a growing database of expert insights on global industries, companies, products, geographies and trends.

Press Contact:
Abigail Crasto
Senior Vice President
101, Arch Street
Boston,
MA 02110
US
Phone +1 (617) 398-1947
abigail@reportsworldwide.com

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Pneumonia Drug Development Pipeline Review, 2017 here

News-ID: 782552 • Views: 148

More Releases from ReportsWorldwide

World Deep Brain Stimulation Market Top Segments, Key Players Revenue, Growth Ra …
The World Deep Brain Stimulation Market is estimated to represent a global market of USD 751.8 million by 2017 with growth rate of 18.2%. Deep brain stimulation (DBS) procedure is primarily used for the treatment of neuropsychiatric disorders such as mood disorder, dementia, anxiety and others. The procedure involve the use of neurotransmitter (brain pacemaker) that enables to transmit electric impulses to the specific target of brain cells. Increasing incidence
New report explores the Gene Editing Market : Ushering The Next Breakthrough in …
Boston, MA ReportsWorldwide has announced the addition of a new report title Gene Editing The Next Breakthrough in Regenerative Medicine to its growing collection of premium market research reports. Genome editing is a type of genetic engineering in which DNA is replaced, inserted or deleted in a living organism's ggenome using engineered molecular scissors. Believed to be one of the great biotechnology breakthroughs, gene editing is a powerful tool in pharmaceutical research that
Global In-Building Wireless BTSController-based Small Cells Market Analysis and …
Boston, MA ReportsWorldwide has announced the addition of a new report title Global In-Building Wireless BTSController-based Small Cells Market Analysis and Forecast, 2017-2021 to its growing collection of premium market research reports. This report covers the leading in-building wireless enterprise BTS/controller-based small cells network equipment manufacturers: • CommScope/Airvana • Comba Telecom • Ericsson • Huawei Technologies • Nokia • SpiderCloud • ZTE Corporation This report covers the global market share for 2016 shipments as well as a forecast for 2017-2021. To view a detailed description and Table of
UDAY’s Impact and Compatibility State wise indexing of Integrated Power Supply …
Boston, MA ReportsWorldwide has announced the addition of a new report title UDAY’s Impact and Compatibility State wise indexing of Integrated Power Supply Chain in India – 2017 to its growing collection of premium market research reports. UDAY scheme was touted as the next paladin to bail out the struggling Discoms, in order to turn them green in a time horizon of 3-4 years from 2015/16. Though was optional for the

All 5 Releases


More Releases for Pneumonia

Global Pneumonia Therapeutics Market 2018 – 2023
Global Pneumonia Therapeutics Market 2018–2023 Poised for xx% Growth Planet Market Research has recently added a market study named Global Pneumonia Market 2018 by Manufacturers, Countries, Type and Application, Forecast to 2023 with prime importance on the forecast period from 2018 to 2023. The report is an in-depth analysis of the market for pneumonia therapeutics and covers various driving factors, restraints, opportunities and challenges affecting the market’s growth. Pneumonia is an
Pneumonia Drug Development Market Focuses on Top Players (Hospital Acquired Pneu …
Pneumonia Drug Development Market study provides comprehensive data which enhances the understanding, scope and application of this report. Polyamides, polyethylene, nylons, epoxy resins, polysulfones, polyphthalamides, polyesters, and polycarbonates are some key forms of plastics that are employed in electronic components. The insulation properties of plastic account for its in depth use in electrical and electronic components of machines and gadgets. Report Consultant has introduced a new report titled as Global Pneumonia
Pneumonia Testing Market Opportunity Analysis, 2018-2026
Pneumonia is a lung infection caused by bacteria, viruses or fungi, primarily affecting the small sir sacs known as alveoli. The most common bacterial type that causes pneumonia is Streptococcus pneumoniae. The symptoms for pneumonia include, fever, chills, cough, shortness of breath and fatigue. To detect whether, a person has pneumonia are blood tests, chest X-ray, pulse oximetry, and Sputum test. Further, if the patients is older than age 65,
Hospital-acquired Pneumonia Drugs Market: to reach over by 2020
Hospital-acquired Pneumonia Drugs Market: Overview Nosocomial or hospital acquired infections have created numerous complications for patients in hospitals throughout the world, as these infections are caused by multidrug resistant microorganisms, the recuperation of a patient is drastically reduced and accompanied by several comorbidities. Being multidrug resistant, these organisms are immune to the conventional antibiotics hence difficult to treat. Pneumonia is one of the prominent infections caused in hospital premises. Cases of
Global Pneumonia Market: Industry Analysis, outlook and Forecast by 2025
An up-to-date research report has been disclosed by Market Research Hub highlighting the title “Global Pneumonia Market Report 2018” which provides an extensive research and detailed analysis of the present market along with future outlook. The report discusses the major growth drivers and challenges of the market, covering U.S, and Europe along with the global market. The report profiles key players of the market including Merck & Co. Inc., Allergan
Pneumonia Diagnostics Market worth US$ 685 Mn by 2027
The World Health Organization estimates that pneumonia accounted for 16% of all deaths of children below the age of 5 years – more than 920,000 in 2015. The WHO states that the cost of pneumonia antibiotic treatment in the same year for child survival and newly born babies is roughly US$ 110 million annually. Therefore, there is a pressing need to analyse the pneumonia diagnostics market. In an upcoming report